Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Physicians Interactive

- PMLiVE

FDA rejects Merck muscle relaxant drug once again

Regulator still has hypersensitivity concerns about Bridion

- PMLiVE

Online doctor collaboration demonstrates value

Developer says web and mobile app iConsult has helped diagnose thousands of cases

What brings patients to pharma websites?

US survey finds doctor recommendations are key for industry site traffic

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

Networks in Health expands into Italy

Online doctors community partners with Merqurio

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

- PMLiVE

Merck & Co drops Parkinson’s prospect preladenant

No better than placebo during phase III trial

- PMLiVE

Merck & Co inches closer to US green light for insomnia drug

FDA panel backs suvorexant, although some concerns about high dosages

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links